TY  - JOUR
AU  - Teichert, Martin
AU  - Stumpf, Christine
AU  - Booken, Nina
AU  - Wobser, Marion
AU  - Nashan, Dorothee
AU  - Hallermann, Christian
AU  - Mogler, Carolin
AU  - Müller, Cornelia S L
AU  - Becker, Jürgen
AU  - Moritz, Rose K C
AU  - Andrulis, Mindaugas
AU  - Nicolay, Jan P
AU  - Goerdt, Sergij
AU  - Thomas, Markus
AU  - Klemke, Claus-Detlev
AU  - Augustin, Hellmut
AU  - Felcht, Moritz
TI  - Aggressive primary cutaneous B-cell lymphomas show increased Angiopoietin-2-induced angiogenesis.
JO  - Experimental dermatology
VL  - 24
IS  - 6
SN  - 0906-6705
CY  - Oxford
PB  - Wiley-Blackwell
M1  - DKFZ-2017-03631
SP  - 424 - 429
PY  - 2015
AB  - Primary cutaneous large B-cell lymphomas, leg type (PCLBCL/LT) are primary cutaneous B-cell lymphoma (PCBCL) with an intermediate prognosis. Therefore, antracycline-based polychemotherapy combined with rituximab has been recommended as first-line treatment. Yet, despite this regimen, the 5-year survival rate remains 50-66
KW  - ANGPT2 protein, human (NLM Chemicals)
KW  - Angiopoietin-2 (NLM Chemicals)
KW  - Integrins (NLM Chemicals)
KW  - Focal Adhesion Protein-Tyrosine Kinases (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:25776770
DO  - DOI:10.1111/exd.12688
UR  - https://inrepo02.dkfz.de/record/127608
ER  -